The National Institute on Aging and Alzheimer’s Association Research’s framework classifies amyloid-positive and tau-negative cases as a biomarker category that indicates AD with concomitant suspected non-Alzheimer’s pathology, either cognitively unimpaired or with mild cognitive impairment (MCI), whether the patient is cognitively unimpaired or has MCI [64]. This evidence concerns the gene MAPT and Cognitive impairment.